The Phase 2 multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of once-daily oral ...

COLUMBUS, Ohio and CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ...

INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to ...

SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic ...

The trade secrets sparring match between Pfizer and Regor Therapeutics has taken a turn in Regor’s favor—albeit a small one—after a federal judge OK’d the biotech’s bid to get a glimpse of Pfizer’s ...

Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients ...

Last month, Pfizer filed a lawsuit against two former executives. The suit claims the pair stole the company’s trade secrets and used the information to set up a competing firm, Regor Therapeutics.

SHANGHAI, CHINA / ACCESSWIRE / December 10, 2021 / Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to ...

COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ...